tbuckley/cabot-search huggingface dataset:
Open Wards in Psychiatric Clinics and Compulsory Psychiatric Admissions
Authors: Andres R. Schneeberger, Christian G. Huber, Undine E. Lang
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
AB0800 Neutrophil: Lymphocyte Ratio and Mean Platelet Volume in Patients with Gout: Table 1.
Authors: A. Balkarli, A. Dogru, Y. Ugan, G. Dogan, S.E. Tunc, M. Sahin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is a clinical syndrome with increased uric acid concentration, which is caused by inflammatory response against mono sodium urate (MSU) crystals. In gout, neutrophils are involved in inflammatory response and neutrophil activation is dependent to local cytokine production. Mean platelet volume (MPV) and neutrophil:lymphocyte ratio (NLR) are considered as inflammatory markers in several diseases and it is reported that they may have prognostic significance. <h3>Objectives</h3> According to current literature, there is no study evaluating MPV and NLR in gout. In this retrospective study, we investigated role of MPV and NLR in determination of inflammation in gout disease. <h3>Methods</h3> In this retrospective study, 106 patients with gout (91 men and 15 women) meeting inclusion criteria by patients records and 148 age- and sex-matched healthy controls (128 men and 20 women) were included. Laboratory data during attacks (group I) and intercritical period (group II) were collected in the patient group. <h3>Results</h3> Mean age was 59.46±12.93 years in the patient group whereas 59.00±11.33 years in the control group. Age at first attack was 52.00±12.77 years and mean time interval between first 2 attacks was 6.00±5.52 months. There was tophus in 9 patients (8.5%) and family history of gout in 17 patients (16.0%). Compared to group 2 (intercritical period) and control, no significant difference in MPV levels was found in the group 1 (during attack). MPV was similar among three groups. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were found to be significantly higher in the group I compared to group II. There was significant difference in NLR among three groups. When classified according to presence of tophus, it was seen that MPV and NLR were similar in both groups. <h3>Conclusions</h3> The finding of increased NLR during attacks and intercritical period shows that patients with gout are subjected to chronic inflammation. Thus, NLR can be simple, inexpensive and useful diagnostic marker in gout. Studies comparing cytokine levels with NLR will be helpful in elucidating this topic. <h3>Disclosure of Interest</h3> None declared
SAT0576 Associations between Five Important Domains of Health and The Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross Sectional Study of 977 Patients
Authors: D. Puyraimond-Zemmour, A. Etcheto, B. Fautrel, A. Balanescu, M. de Wit, T. Heiberg, K. Otsa, T.K. Kvien, M. Dougados, L. Gossec
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The objectives of treatments in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) include acceptable quality of life from the patient9s perspective. One simple question can be used to evaluate the level of acceptability of the disease status by a patient: the patient acceptable symptom state (PASS) which corresponds to the concept of “feeling well”. <h3>Objectives</h3> The objective was to explore the link between a patient acceptable symptom state (PASS) and patient-perceived impact in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). <h3>Methods</h3> Cross-sectional study of unselected patients with definite RA or PsA. Five domains of health were analysed: Pain, functional capacity, fatigue, coping and sleep disturbance. They were assessed by a numeric rating scale (0–10) and were compared between patients in PASS or not (Cohen9s effect sizes). The domains of health associated with PASS status were assessed by multivariate logistic regression, and PASS thresholds were determined using the 75th percentile method and ROC analyses. <h3>Results</h3> Among 977 patients (531 RA, 446 PsA) mean age was 53.4±13.2 yrs; mean disease duration was 11.2±10.0 yrs; 637 (65.8%) were females. In all, 595 patients (60.9%) were in PASS: they had lower symptom levels, and all domains of health except sleep disturbance discriminated clearly between patients in PASS or not (effect sizes, 0.73 to 1.45 in RA and 0.82 to 1.41 in PsA). In multivariate analyses, pain and coping were predictive of not being in PASS: odds ratio [95% confidence interval] 0.81 [0.67–0.96] and 0.63 [0.52–0.75] for pain and 0.84 [0.74–0.96] and 0.83 [0.71–0.97] for coping, in RA and PsA respectively. The cut-offs of symptom intensity (range 0–10) corresponding to PASS for the five domains of health and the two diseases with a score were similar, i.e. around 4–5. <h3>Conclusions</h3> Two thirds of 977 unselected tertiary care patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) were in PASS. In RA and PsA, PASS was associated with the five domains of health analysed, and in particular with less pain and better coping. PASS levels in the two diseases for the five domains of health, as well as the RAID and PsAID scores were similar with cut-offs around 4–5 points (0–10 scale). <h3>References</h3> Gossec L. et al, Ann Rheum Dis, 2014. Gossec L. et al, Ann Rheum Dis 2009. <h3>Disclosure of Interest</h3> None declared
Actin Is Crucial for All Kinetically Distinguishable Forms of Endocytosis at Synapses
Authors: Xin-Sheng Wu, Sung Hoon Lee, Jiansong Sheng, Zhen Zhang, Wei-Dong Zhao, Dongsheng Wang, Yinghui Jin, Patrick Charnay, James M. Ervasti, Ling-Gang Wu
Journal: Neuron (2016)
Response to ‘A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier’
Authors: V.A. Hart
Journal: British Journal of Dermatology (2016)

I read, with interest, the recent article by Danby et al1 on the effectiveness of two commercially available emollients, Diprobase cream and Doublebase gel, in relation to the structure and function of the skin barrier in atopic dermatitis.

This article is protected by copyright. All rights reserved.
Proteomic Analysis of Plasma Exosome-Associated Proteins Reveals That Differences In Kappa:Lambda Ratios Predict Severe Acute Graft-Versus-Host Disease Early After Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Joseph L Alge, Michael Janech, John Schwacke, John Arthur, Luciano J Costa
Journal: Blood (2010)
Comparative Study of Hematopoietic Lineage Potential of Ips Cells Derived From Two Mesodermal Cell Lineages
Authors: Roksana Moraghebi, Roger Emanuel Rönn, Claudia Stolz, Patricia Chaves Guerrero, Aaron Parker, Andreas Herbst, Marcus Larsson, Ewa Sitnicka, Inder Verma, Niels-Bjarne Woods
Journal: Blood (2011)
SP0071 The Role of Young Pare in Getting Organised: The Virtual Knowledge Centre
Authors: P. Balazova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The EULAR Young PARE working group launched the Virtual Knowledge Centre (VKC) in March 2016. The VKC is an online toolbox exclusively for the Young PARE network of liaison persons. Liaison persons are representatives of European national organisations, with particular interests in supporting young people with rheumatic and musculoskeletal diseases (RMDs). The VKC can be found on www.youngpare.org. <h3>Objectives</h3> The objectives of the VKC were to: (1) establish a database with information about national youth organisations; (2) create the European network of RMD youth groups to exchange best practices; (3) provide support to national youth organisations; and (4) ensure that national youth organisations, via liaison persons stay in contact with each other to share knowledge and experiences. <h3>Methods</h3> The VKC interface offers the possibility to see the members of EULAR Young PARE, upload and download best practices and interact with other members via a moderated forum. The VKC is secure, and requires users to login, once approved by a moderator. When logged in members are able to send private messages to each other. <h3>Results</h3> The VKC has been designed to help patient organisations to collaborate and share knowledge about their work. It provides support to the network through interaction and gives the opportunity to communicate with each other in a secure and safe environment. <h3>Conclusions</h3> EULAR Young PARE is continuing to improve the VKC through gathering best practices and feedback from its members. EULAR Young PARE will also work on more effective management strategies of the forum, to ensure the VKC becomes a lively environment. <h3>Acknowledgement</h3> Simon Stones, Linda Van Nieuwkoop, Jeanette Andersen, Theodora Papastavrou, Nele Caeyers, Florian Klett <h3>References</h3> EULAR Young PARE (2016). Virtual Knowledge Centre. Available from: http://vkc.youngpare.org [Accessed 15 March 2016]. <h3>Disclosure of Interest</h3> None declared
Immunological, Molecular and Cytokine Changes after Reduced Intensity Bone Marrow Transplantation for PNH: A 2 Years Follow-Up.
Authors: Wilma Barcellini, Francesca G. Imperiali, Anna Zaninoni, Elisa Fermo, Carla Boschetti, Davide Soligo, Giorgio Lambertenghi Deliliers, Alberto Zanella
Journal: Blood (2005)
AB0325 Clinical outcome of 2 years treatment of the early phase rheumatoid arthritis
Authors: Y. Sugimura, T. Kashiwagura, M. Kobayashi, N. Miyakoshi, Y. Shimada
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Few studies have reported long term clinical outcome of patients with early phase rheumatoid arthritis (RA). <h3>Objectives</h3> The objectives of this study were to investigate outcome of 2 years treatment for RA which was started less than 12 months after RA symptoms first appeared and to evaluate prediction factors of poorly controlled patients at 2 years. <h3>Methods</h3> From a total of 1663 RA patients registered in the Akita Orthopaedic Group on Rheumatoid Arthritis (AORA), 66 patients were treated within the first year of RA appearance, and enrolled in this study. Sex, age, RA disease duration, Steinbroker's stage, Steinbroker's class, medications and DAS28-CRP at the baseline and 2 years post-treatment were evaluated. Furthermore, we compared the group of remission (REM) or low disease activity (LDA) with the group of medium disease activity (MDA) or high disease activity (HDA) at 2 years. <h3>Results</h3> At the baseline, the patients included 13 males and 53 females. Mean age and RA disease duration were 59<sup>21–85</sup> years and 7<sup>1–11</sup> months, respectively. Fifty-four, 8, 4 and 0 patients were classified into Steinbroker's stage I, II, III, and IV, respectively. Thirty-nine, 25, 2 and 0 patients were classified into Steinbroker's class I, II, III, and IV, respectively. Thirty-seven (56%), 24 (36%), and 16 (24%) patients were treated with MTX, DMARDs, and PSL, respectively. In DAS28-CRP, 19 (29%), 13 (20%), 32 (48%), and 2 (3%) patients showed REM, LDA, MDA, and HDA, respectively. Forty-four patients were followed-up for 2 years. At 2 years, 30, 7, 5, and 2 patients were classified into Steinbroker's stage I, II, III, and IV, respectively. Thirty-one, 12, 1, and 0 patients are classified into Steinbroker's class I, II, III, and IV, respectively. In DAS28-CRP, 33 (75%), 4 (9%), 7 (16%), and 0 (0%) patients showed REM, LDA, MDA, and HDA, respectively. Compared with the group of REM or LDA, the group of MDA or HDA had significantly older age (p=0.018), higher Steinbroker's stage (p=0.012) and higher DAS28-CRP (p=0.049) at the baseline. <h3>Conclusions</h3> At 2 years, 75% of patients with early phase RA achieved REM. Older age, higher Steinbroker's stage and higher DAS28-CRP at the baseline could be prediction factors of poorly controlled patients at 2 years. <h3>Disclosure of Interest</h3> None declared
AB0844 Comparing of The Effectiveness of Botilinum Toxin Type-A and Prilocaine Injections Clinically in The Treatment of Myofascial Pain Syndrome
Authors: B. Özdemir, Ö. Köroğlu, T. Dandinoglu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> The objective of this study was to compare the effects of botulinum toxin-A (BTX-A) injection and prilocaine injection in the treatment of myofascial pain syndrome (MAS). <h3>Methods</h3> Thirty eight patients, having trigger points in the muscles diagnosed as MAS were analyzed in this randomized, single blind, comparative study. <i>Setting:</i> Patients were randomized into two treatment groups namely BTX-A injection group and prilocaine group. Each group consisted of 19 patients. <i>Intervention:</i> In BTX-A injection group, 10 U of BTX was injected to each trigger point. In the prilocaine group 2ml prilocaine was injected to each trigger point. All the patients were asked to do stretching exercises at home. <i>Main outcome measure:</i> Treatment efficacy was evaluated clinically before and 2 and 6 weeks after treatment. Evaluation parameters were during function visual analog scale (VAS), pain score (PS), pain pressure threshold (PPT), general well-being by short form-36 (SF-36) and Beck Depression Inventory (BDI). <h3>Results</h3> Statistically significant improvements were observed during function VAS, PS, PPT, SF36 and BDI in both treatment group. Improvement in VAS and PPT at 2 weeks was more significant in the BTX-A group. Improvement in VAS, PPT, PS at 6 weeks was more significant in BTX-A group. There is no difference between two groups in BDI. Borderline improvement was observed in BTX-A group at 6 weeks. <h3>Conclusions</h3> BTX-A injections and prilocain injections are the beneficial treatment choices in this syndrome. But we observed the progressive cumulative effect of BTX-A in the course of time. Although cost effectivity limitation we suggest that patients with chronic persistant myofascial trigger points can be convenient candidates for BTX-A injections. Adjuvant appropriate exercises program should be included in primary treatment modality for optimal success. <h3>Disclosure of Interest</h3> None declared
THU0596 Physician's Global Assessment of Disease Activity in Rheumatoid Arthritis, Reflects Solely Objective Measures and Disregards Patient Reported Outcomes: Table 1.
Authors: G. Eugenio, R. Ferreira, C. Silva, C. Duarte, J.A.P. Silva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Physician9s global assessment of disease activity (PhGA) has been shown to be a determinant factor for therapeutic decisions in Rheumatoid Arthritis (RA). The adequacy of this assessment is, therefore crucial, to assure that the best options are taken in the perspective of the patient9s interest. <h3>Objectives</h3> To evaluate the determinants of PhGA, including clinical variables and patient reported outcomes. <h3>Methods</h3> Consecutive RA patients followed in a Tertiary Rheumatology Department were included in this cross-sectional study. Patient demographics and clinical assessments were collected through a standardized protocol which included age, gender, disease duration, DAS(28)4v-CRP (and its individual measures), DAS(28)4v, pain (VAS 0–100mm), Patient Global Assessment (PGA) of disease activity (VAS 0–100mm) and function (Health Assessment Questionnaire (HAQ)). From physicians were collected PhGA (VAS 0–100 mm), summary score of the patient9s mobility and deformity (VAS 0–100mm). To identify independent predictors of PhGA, Pearson9s Correlation Coefficient was used to select variables (p&lt;0.05) to subsequent inclusion in multivariable linear regression (stepwise model). <h3>Results</h3> 311 patients were included: 81.7% females, 60±12 years, 11±9 years of disease duration, 8±5 years of formal education and a mean DAS(28)4v-CRP=2.9±1.2. PhGA was statistically and strongly associated only with swollen joint count (SJC28) (r=0.71). Moderate correlations were observed with tender joint count (TJC28) (r=0.41), DAS(28)3v–CRP (r=0.655) and DAS(28)3v (r=0.550). Weak correlations (r&lt;0.4) were observed with pain, PGA, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and HAQ, as well as with mobility and deformity in the physician9s perspective. In multivariable analysis, SJC28 (β=5.02, 95%CI: 4.29;5.73, p&lt;0.001) and CRP (β=3.0, 95%CI: 1.56;4.46, p&lt;0.001) were the most significant predictors of PhGA, with a small contribution of the physicians assessment of patient mobility. <h3>Conclusions</h3> Physicians consider objective measures when assessing disease activity, apparently disregarding pain and the PGA. This may lead to suboptimal management approaches from the patient9s perspective, especially regarding disease dimensions that are not directly affected by immunosuppressive therapy. <h3>Disclosure of Interest</h3> None declared
PTU-152 Prediction of Malignant Progression of Barrett’s Oesophagus – A Complete Systematic Review and Meta-Analysis
Authors: K Altaf, J Xiong, L Hickey, A Kaul
Journal: Gut (2016)

<h3>Introduction</h3> Barrett’s Oesophagus (BO) is a precursor for Oesophageal Adenocarcinoma (OAC). Currently, there are no biomarkers in clinical practice that predict the malignant progression in BO. We sought to clarify the effectiveness of common genetic aberrations as potential biomarkers in this context through a systematic review and meta-analyses. <h3>Methods</h3> MEDLINE, EMBASE and the Cochrane Library were searched by two independent reviewers to identify all clinical studies that assessed efficacy of p53, p16, Ki-67 and DNA content abnormalities as prognostic markers in BO. The main outcome measure was development of OAC. review and meta-analyses. <h3>Results</h3> 104 clinical studies, with 12,353 samples were identified. Mutation [DOR 10.91 (2.46–48.42), sensitivity 47% (41–53%), specificity 92% (90–94%), PLR 4.71 (1.73–12.78), NLR 0.65 (0.50–0.85), AUC 0.7921] and loss of p53 [DOR 16.16 (6.09–42.88), sensitivity 31% (25–38%), specificity 98% (97–98%), PLR 6.66 (4.51–9.84), NLR 0.41 (0.11–1.47), AUC 0.9228] were found to be superior to the other p53 abnormalities (Loss of heterozygosity and Over-expression). Ki-67 was also noted to have high sensitivity in identifying high risk patients [DOR 5.54 (3.40–9.05), sensitivity 82% (78–85%), specificity 48% (44–52%), PLR 1.59 (1.20–2.10), NLR 0.42 (0.34–0.51), AUC 0.7607]. Aneuploidy [DOR 12.08 (8.09–18.03), sensitivity 53% (50–57%), specificity 87% (85–88%), PLR 4.26 (2.92–6.20), NLR 0.42 (0.32–0.55), AUC 0.8461], tetraploidy [DOR 5.87 (2.56–13.4), sensitivity 46% (39–53%), specificity 85% (82–87%), PLR 3.47 (1.98–6.05), NLR 0.65 (0.45–0.94), AUC 0.7926] and loss of Y chromosome [DOR 9.23 (4.34–19.63), sensitivity 68% (56–79%), specificity 80% (73–86%), PLR 2.67 (1.29–5.50), NLR 0.49 (0.35–0.68), AUC 0.8073] also predicted the malignant development with respectable accuracy but p16 aberrations [{Hypermethylation - DOR 3.00 (2.02–4.45), sensitivity 56% (51–61%), specificity 63% (59–66%), PLR 1.68 (1.35–2.08) (1.32–1.72), NLR 0.66 (0.54–0.80), AUC 0.6773}, {LOH - DOR 4.19 (1.85–9.53), sensitivity 55% (47–62%), specificity 54% (50–58%), PLR 1.84 (1.13–2.99), NLR 0.73 (0.60–0.88), AUC 0.6915}, {Mutation - DOR 1.61 (0.86–3.01), sensitivity 18% (13–24%), specificity 86% (83–89%), PLR 1.53 (0.97–3.42), NLR 0.96 (0.87–1.04), AUC 0.6890}, {Loss - DOR 2.18 (1.18–4.01), sensitivity 58% (53–63%), specificity 58% (53–63%), PLR 1.51 (1.08–1.95), NLR 0.74 (0.56–0.97), AUC 0.6314}] failed to demonstrate any advantage over the other biomarkers studied. <h3>Conclusion</h3> Loss and mutation of p53 and Ki-67 effectively predict malignant progression in BO. A panel of biomarkers would be more suited to be included in surveillance programme. This will need to be confirmed in large, prospective clinical trials with cost- efficiency analyses. <h3>Disclosure of Interest</h3> None Declared
THU0100 Serum Leptin as A Biomarker of Fat Mass Excess in Rheumatoid Arthritis Brazilian Patients
Authors: M.F. Guimaraes, C.J. Machado, E.L.M. Vieira, M.R.C. Pinto, M.V. Andrade, A.L. Junior, A. Kakehasi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> although obesity is a risk factor for developing coronary artery disease<sup>1</sup> and cardiovascular diseases account for approximately half of the deaths among rheumatoid arthritis (RA) patients<sup>2</sup>, anthropometric measures are not accurate for fat mass quantification in this population.<sup>3</sup> <h3>Objectives</h3> to identify a serum biomarker of fat excess in patients with RA. <h3>Methods</h3> cross-sectional study in adults with established RA. Disease activity was assessed by DAS28 and CDAI. Anthropometric measures included waist circumference (WC), weight and height for body mass index (BMI) calculation. Body composition by DXA (Hologic Discovery W, software 3.3.01) was used to fat mass excess quantification.<sup>4</sup> Circulating levels of IL-6, TNF alpha, IL- 1β and leptin were measured in a single sample of peripheral blood using the technique of Bead-Based Multiplex Immunoassays- Luminex; while adiponectin was measured by Enzyme-Linked Immunosorbent Assay-ELISA. <h3>Results</h3> 99 patients were included, 89.9% women, with mean age of 54.5 (±11) years and mean disease duration of 16.5 (±9.3) years. The frequency of obesity was 31.3% by BMI, 85.9% by WC and 57.6% by DXA. Mean serum leptin concentration was 24.5 (± 22.5) ng/ml. Leptin correlated with obesity by the three methods: BMI, WC and DXA. This correlation was stronger with DXA. The correlation between leptin and DXA was not influenced by DAS28, C-reactive protein, erythrocyte sedimentation rate, nor by inflammatory cytokines levels (IL -6, TNF-alpha, IL- 1β). Analysis by ROC curve determined the cut-off point of 6.52 ng/ml of leptin as obesity marker, with a sensitivity of 96.43% and a specificity of 23.81%. <h3>Conclusions</h3> serum concentration of leptin presents as a fat mass excess biomarker, being useful since more accurate diagnostic methods for measuring fat mass are not available in clinical practice. <h3>References</h3> Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50(11):3450–7. Myasoedova E, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol. 2010;22(3):342–7. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis. 2007;66(10):1316–21. Bray G. Contemporary Diagnosis and Management of Obesity and the Metabolic Syndrome. Handbooks in Health Care: Newtown, PA, 2003. <h3>Disclosure of Interest</h3> None declared